ODS 2004436

Drug Profile

ODS 2004436

Alternative Names: ODS-2004436

Latest Information Update: 24 Aug 2016

Price : $50

At a glance

  • Originator Oncodesign Biotechnology
  • Developer Centre Georges Francois Leclerc; Oncodesign Biotechnology
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lung cancer

Most Recent Events

  • 01 Sep 2016 Oncodesign initiates enrolment in a phase I trial for ODS 2004436 in France
  • 12 Jul 2016 Phase-I clinical trials in Lung cancer (Diagnosis) in France (Parenteral)
  • 29 Mar 2016 Oncodesign files a clinical trial applcation with the French regulatory authorities before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top